方盛制药：公司目前在销产品主要有中药创新药和部分经典中成药

Core Viewpoint - Fangsheng Pharmaceutical (603998) emphasizes its focus on innovative traditional Chinese medicine (TCM) and classic TCM products, highlighting their clinical value and adherence to regulatory standards [1] Product Overview - The company’s main products include innovative TCM such as Xiaoer Jingxing Zhike Granules, Xuanqi Jianguo Tablets, and Yangxue Qufeng Zhitong Granules, all of which have undergone Phase II and III clinical trials [1] - Innovative TCM products are based on TCM theory and clinical practice, featuring breakthroughs in formulation, process, and standards, with strict quality control and minimal side effects due to their natural origins [1] - Classic TCM products include Tenghuang Jianguo Tablets, Xuesaitong Tablets/Dispersible Tablets, and Qiangli Pipa Syrup (Honey-Processed)/Liquid, which have completed or are in the process of revising safety content in their instructions [1] Regulatory Compliance - The company is attentive to regulatory policy adjustments in the TCM industry and prioritizes the safety and efficacy of its products, ensuring compliance with national drug regulatory requirements in its production and R&D activities [1]